Holen Sie sich die Stockscreener-App
154.98
2.09%
3.17
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026? - The Globe and Mail
BofA Raises PT on Gilead Sciences (GILD) to $162 From $154Here's Why - Bitget
BofA Raises PT on Gilead Sciences (GILD) to $162 From $154 – Here’s Why - Insider Monkey
Focus on These 5 Stocks That Recently Hiked Dividends - TradingView
Gilead Sciences Inc (NASDAQ:GILD) Offers a Sustainable Dividend Backed by Strong Fundamentals - ChartMill
Longbow Finance SA Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says - MarketBeat
TD Cowen Raises Gilead Sciences (NASDAQ:GILD) Price Target to $160.00 - MarketBeat
Varma Mutual Pension Insurance Co Has $22.71 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
ING Groep NV Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
LSV Asset Management Has $477.26 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Leuthold Group LLC Takes $4.73 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences stock price target raised to $170 from $155 at Wolfe Research - Investing.com
Illinois Municipal Retirement Fund Buys 10,657 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Caisse Des Depots ET Consignations Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
GILD Gilead Sciences: Scotiabank Maintains Outperform, PT $177 Feb 2026 - Meyka
Gilead Sciences (GILD) Net Margin Reset Challenges Slower Growth Narratives In FY 2025 Results - Sahm
Xilio Therapeutics Announces Pricing of Underwritten Offering - GlobeNewswire Inc.
Gilead Sciences Stock Spikes After Q4 Results: Time to Buy? - Yahoo Finance
Gilead Sciences Earnings Call: HIV Strength, New Catalysts - TipRanks
Gilead Accuses Cipla of Sidestepping Earlier Descovy Patent Deal - Bloomberg Law News
Yescarta Label Expansion And Dividend Growth Shape Gilead Investment Case - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) to Issue Dividend Increase$0.82 Per Share - MarketBeat
Key facts: Gilead Q4 profit hits $2.18B; signs MoU with UAE Health - TradingView
Morgan Stanley Sees Gilead Gaining Ground In HIV And Oncology - Finimize
TD Cowen Adjusts Gilead Sciences Price Target to $160 From $145, Maintains Buy Rating - marketscreener.com
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Truist Financial Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Buy Rating on Gilead: Solid Core Growth, Conservative Guidance, and Late-Stage Pipeline Upside Into 2026 - TipRanks
Gilead Sciences Poised for Yeztugo Execution, Pipeline Upside in 2026, Morgan Stanley Says - marketscreener.com
‘Pieces are coming together’ amid Gilead's Yeztugo launch: exec - Fierce Pharma
GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales - Finviz
GILD: Wells Fargo Raises Price Target for Gilead Sciences | GILD Stock News - GuruFocus
Gilead's Long HIV Patent Life and Emerging Oncology Portfolio Support a Wide Moat - Morningstar
Oppenheimer Adjusts PT on Gilead Sciences to $165 From $128, Maintains Outperform Rating - marketscreener.com
Truist Securities raises Gilead Sciences stock price target to $152 - Investing.com India
Gilead Sciences (NASDAQ:GILD) Hits New 1-Year High on Earnings Beat - MarketBeat
Gilead Sciences Stock Surges to Record Highs Amid Bull Notes - Schaeffer's Investment Research
Bernstein raises Gilead Sciences stock price target to $160 on growth outlook - Investing.com
Gilead Sciences stock holds steady as Goldman Sachs maintains Neutral rating - Investing.com
Gilead Sciences stock holds steady as Goldman Sachs maintains Neutral rating By Investing.com - Investing.com India
Gilead Sciences stock hits all-time high at $153.32 By Investing.com - Investing.com India
Gilead Sciences stock hits all-time high at $153.32 - Investing.com
Gilead Sciences stock price target raised to $160 from $150 at BMO Capital - Investing.com
Gilead Sciences stock price target raised to $160 from $150 at BMO Capital By Investing.com - Investing.com India
Morgan Stanley Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
GILD: Scotiabank Raises Gilead Sciences Price Target Amidst Sect - GuruFocus
Gilead Sciences stock price target raised to $162 from $154 at BofA - Investing.com
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $177.00 - MarketBeat
Cantor Fitzgerald Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $155.00 - MarketBeat
Gilead Sciences signs MoU with Ministry of Health and Prevention - ZAWYA
Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings - Benzinga
Gilead Sciences (GILD) PT Raised to $162 at BofA Securities - StreetInsider
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $155 to $177 - 富途牛牛
Gilead Sciences (GILD) Q4 2025 adj. earnings decline, despite higher revenues - AlphaStreet News
Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2025 Earnings Call Transcript - Insider Monkey
Gilead To Stay ‘Proactive And Disciplined’ With Deals But M&A Not Urgent Priority - BioSpace
Rhumbline Advisers Sells 15,602 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Needham & Company LLC Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Needham raises Gilead Sciences stock price target to $170 on strong HIV sales - Investing.com India
JPMorgan Adjusts Price Target on Gilead Sciences to $160 From $150, Maintains Overweight Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Gilead Sciences to $165 From $150, Maintains Overweight Rating - marketscreener.com
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):